By

Luke Timmerman

19
Dec
2022

A New Way to Treat Depression: Barry Greene on The Long Run

Today’s guest on The Long Run is Barry Greene. Barry is the CEO of Cambridge, Mass.-based Sage Therapeutics. Sage is developing a new medicine for the treatment of major depressive disorder and postpartum depression. Sage, and its partner, Biogen, recently completed a New Drug Application to the FDA for permission to start marketing zuranolone. The drug is a once-daily oral...
Read More
7
Nov
2022

Delivery of Genetic Medicines: Shehnaaz Suliman on The Long Run

Today’s guest on The Long Run is Shehnaaz Suliman. Shehnaaz is the CEO of Menlo Park, California-based ReCode Therapeutics. Recode is working on lipid nanoparticles to improve the delivery of genetic medicines. These little packages have made it possible to deliver billions of mRNA COVID vaccines in people’s arms, saving millions of lives. It’s been two decades of hard work....
Read More
11
Oct
2022

Protein Degraders For Outside the Cell: Aetna Wun Trombley on The Long Run

Today’s guest on The Long Run is Aetna Wun Trombley. Aetna is the CEO of South San Francisco-based Lycia Therapeutics. Many in biotech know about targeted protein degraders. Arvinas and Kymera Therapeutics are a couple of the well-known companies that make these drugs which work to inhibit intracellular proteins. This approach has drawn a lot of excitement because it can...
Read More
6
Oct
2022

The Kilimanjaro Climb to Fight Cancer Is Back

I’m taking another biotech team to the highest peak in Africa. Four years after the first team expedition, the Kilimanjaro Climb to Fight Cancer is back with a new crew of 28 biotech executives and investors. Together, we’re going to push ourselves physically, and raise more than $1 million for research at the Fred Hutch Cancer Center. The expedition is...
Read More